TWI705827B - 治療眼部疾病之方法 - Google Patents

治療眼部疾病之方法 Download PDF

Info

Publication number
TWI705827B
TWI705827B TW104135104A TW104135104A TWI705827B TW I705827 B TWI705827 B TW I705827B TW 104135104 A TW104135104 A TW 104135104A TW 104135104 A TW104135104 A TW 104135104A TW I705827 B TWI705827 B TW I705827B
Authority
TW
Taiwan
Prior art keywords
week
weeks
bcva
compared
vegf antibody
Prior art date
Application number
TW104135104A
Other languages
English (en)
Chinese (zh)
Other versions
TW201625306A (zh
Inventor
瑪格麗特 吉凱法
詹姆斯 瓦柏頓
安德列斯 維奇賽柏格
彼得 賽斯提格
沃納 舒密特
Original Assignee
瑞士商諾華公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54697654&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI705827(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 瑞士商諾華公司 filed Critical 瑞士商諾華公司
Publication of TW201625306A publication Critical patent/TW201625306A/zh
Application granted granted Critical
Publication of TWI705827B publication Critical patent/TWI705827B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/12—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW104135104A 2014-11-07 2015-10-26 治療眼部疾病之方法 TWI705827B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462076770P 2014-11-07 2014-11-07
US62/076,770 2014-11-07
US201462088061P 2014-12-05 2014-12-05
US62/088,061 2014-12-05

Publications (2)

Publication Number Publication Date
TW201625306A TW201625306A (zh) 2016-07-16
TWI705827B true TWI705827B (zh) 2020-10-01

Family

ID=54697654

Family Applications (4)

Application Number Title Priority Date Filing Date
TW110133255A TWI806150B (zh) 2014-11-07 2015-10-26 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
TW109132401A TWI761959B (zh) 2014-11-07 2015-10-26 治療眼部疾病之方法
TW104135104A TWI705827B (zh) 2014-11-07 2015-10-26 治療眼部疾病之方法
TW104135105A TWI738632B (zh) 2014-11-07 2015-10-26 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
TW110133255A TWI806150B (zh) 2014-11-07 2015-10-26 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
TW109132401A TWI761959B (zh) 2014-11-07 2015-10-26 治療眼部疾病之方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW104135105A TWI738632B (zh) 2014-11-07 2015-10-26 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物

Country Status (24)

Country Link
US (5) US10035850B2 (OSRAM)
EP (2) EP3215122B1 (OSRAM)
JP (6) JP6667519B2 (OSRAM)
KR (4) KR20170082526A (OSRAM)
CN (4) CN120938921A (OSRAM)
AU (6) AU2015342815B2 (OSRAM)
BR (2) BR112017008660A2 (OSRAM)
CA (1) CA2966646A1 (OSRAM)
CL (2) CL2017001115A1 (OSRAM)
CO (1) CO2017004596A2 (OSRAM)
EA (1) EA201790989A1 (OSRAM)
EC (1) ECSP17034829A (OSRAM)
GT (1) GT201700096A (OSRAM)
IL (5) IL251642B (OSRAM)
MX (3) MX383399B (OSRAM)
MY (2) MY193913A (OSRAM)
NZ (1) NZ730821A (OSRAM)
PE (1) PE20170780A1 (OSRAM)
PH (3) PH12021550147A1 (OSRAM)
RU (1) RU2722643C2 (OSRAM)
SG (3) SG11201702909QA (OSRAM)
TN (1) TN2017000128A1 (OSRAM)
TW (4) TWI806150B (OSRAM)
WO (2) WO2016073918A1 (OSRAM)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007237096C1 (en) 2006-04-07 2012-12-13 EyePoint Pharmaceuticals, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
WO2009155723A2 (en) 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
MX345395B (es) 2008-06-25 2017-01-30 Esbatech Alcon Biomed Res Unit Humanizacion de anticuerpos de conejos usando una estructura de anticuerpos universal.
CA2748765C (en) 2009-07-06 2014-07-22 Akebia Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
CA2824422A1 (en) 2011-01-13 2012-07-19 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
EP3505182A1 (en) 2011-10-13 2019-07-03 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
CN106456614A (zh) 2014-03-14 2017-02-22 爱尔皮奥治疗有限公司 HPTP‑β抑制剂
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
US10894083B2 (en) 2015-01-28 2021-01-19 Pfizer Inc. Stable aqueous anti-vascular endothelial growth factor (VEGF) antibody formulation
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
MX387804B (es) 2015-09-23 2025-03-19 Aerpio Therapeutics Inc Metodos para tratar presion intraocular con activadores de tie-2
SG10202109655VA (en) 2015-12-04 2021-10-28 Novartis Ag Compositions and methods for immunooncology
CA3010056A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
WO2018017714A1 (en) 2016-07-20 2018-01-25 Aerpio Therapeutics, Inc. HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
EP3509623A4 (en) * 2016-09-07 2020-06-03 Saksin Lifesciences PVT Ltd SYNTHETIC ANTIBODIES TO VEGF AND USES THEREOF
EP3518971A4 (en) * 2016-09-28 2020-05-13 Board Of Regents, The University Of Texas System Antibody and protein therapeutic formulations and uses thereof
EP3543337B1 (en) 2016-11-18 2022-04-20 Astellas Pharma Inc. Novel anti-human muc1 antibody fab fragment
JP2020513832A (ja) 2017-03-22 2020-05-21 ノバルティス アーゲー 免疫腫瘍学のための組成物および方法
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
WO2018195912A1 (zh) * 2017-04-28 2018-11-01 苏州思坦维生物技术股份有限公司 一种眼用药物组合物及其用途
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
WO2019020777A1 (en) * 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
WO2019071205A1 (en) 2017-10-06 2019-04-11 Prothena Biosciences Limited ANTI-TRANSTHYRETIN ANTIBODY
CN111757730A (zh) 2017-10-06 2020-10-09 普罗塞纳生物科学有限公司 检测甲状腺素运载蛋白的方法
BR112020010483A2 (pt) * 2017-11-29 2020-10-20 Prothena Biosciences Limited formulação liofilizada de um anticorpo monoclonal contra transtirretina
EP4609914A3 (en) 2017-11-30 2025-10-15 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
JP7005772B2 (ja) * 2018-02-06 2022-02-10 エフ．ホフマン－ラ ロシュ アーゲー 眼科疾患の処置
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
CN111867631A (zh) * 2018-03-16 2020-10-30 诺华股份有限公司 治疗眼部疾病的方法
WO2019180261A1 (en) * 2018-03-23 2019-09-26 AbbVie Deutschland GmbH & Co. KG Stable aqueous anti-tau antibody formulations
CN112262158B (zh) * 2018-04-10 2024-08-09 奥美药业有限公司 新型血管生成素2，vegf双特异性拮抗剂
IL318714A (en) 2018-05-10 2025-03-01 Regeneron Pharma Formulations that include high concentrations of VEGF receptor fusion protein
WO2019221269A1 (ja) 2018-05-17 2019-11-21 アステラス製薬株式会社 抗ヒトＭＵＣ１抗体Ｆａｂフラグメント、ペプチドリンカー及び／又は配位子を含む複合体
EP3856245A4 (en) 2018-09-24 2022-10-26 EyePoint Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - ß (VE-PTP) AND VEGF
TW202027794A (zh) 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送
CN112839683B (zh) * 2018-10-10 2023-11-14 安斯泰来制药株式会社 含有标记部-抗人抗体Fab片段复合物的药物组合物
MX2021004774A (es) * 2018-10-29 2021-08-24 Hoffmann La Roche Formulacion de anticuerpos.
SG11202104734YA (en) 2018-11-07 2021-06-29 Applied Molecular Transport Inc Cholix-derived carriers for oral delivery of heterologous payload
KR20210106476A (ko) * 2018-12-18 2021-08-30 노파르티스 아게 고농도의 항-vegf 항체를 함유하는 단백질 용액 제형
JP7266108B2 (ja) 2019-02-18 2023-04-27 イーライ リリー アンド カンパニー 治療用抗体製剤
TW202532428A (zh) 2019-04-26 2025-08-16 美商愛德維仁生物科技公司 用於玻璃體內遞送之變異體aav蛋白殼
JP7564824B2 (ja) 2019-04-29 2024-10-09 アイポイント ファーマシューティカルズ， インコーポレイテッド シュレム管を標的とするＴｉｅ－２活性化物質
BR112022002962A2 (pt) 2019-08-16 2022-07-05 Applied Molecular Transport Inc Composições, formulações e produção e purificação de interleucina
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
CN111217834B (zh) * 2020-02-21 2021-10-26 维眸生物科技（上海）有限公司 Rock激酶抑制剂的硝基氧衍生物
AU2021232369B2 (en) * 2020-03-04 2025-06-05 Shanghai Henlius Biotech, Inc. Pharmaceutical formulation comprising bevacizumab
CN113698478B (zh) * 2020-05-21 2025-11-18 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其稳定制剂
KR20220001106A (ko) 2020-06-29 2022-01-05 (주)메디톡스 고농도 항-ｖｅｇｆ 항체 제제 및 이에 사용하기 위한 항-ｖｅｇｆ 항체
AU2021308712B2 (en) 2020-07-16 2025-10-09 Novartis Ag Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
AU2022275786C1 (en) * 2021-05-17 2025-12-11 Bayer Healthcare Llc Extended, high dose VEGF antagonist regimens for treatment of angiogenic eye disorders
CN113940997B (zh) * 2021-12-21 2022-04-08 迈威(上海)生物科技股份有限公司 一种双特异性抗体的稳定制剂
AU2023340359A1 (en) * 2022-09-16 2025-04-17 Qilu Pharmaceutical Co., Ltd. Stable high-concentration self-buffering pharmaceutical composition
WO2025231345A1 (en) * 2024-05-03 2025-11-06 Therini Bio, Inc. Doses of antibodies which bind human fibrin yc or fibrinogen yc domain for ocular diseases

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2005299701B2 (en) * 2004-10-21 2011-11-17 Genentech, Inc. Method for treating intraocular neovascular diseases
WO2007011873A2 (en) * 2005-07-15 2007-01-25 Genentech, Inc. Method for treating intraocular neovascular diseases
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US7608261B2 (en) 2006-06-16 2009-10-27 Regeneron Pharmacuticals, Inc. VEGF antagonist formulations suitable for intravitreal administration
PE20090329A1 (es) 2007-05-30 2009-03-27 Abbott Lab Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
TWI580694B (zh) 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
MX345395B (es) 2008-06-25 2017-01-30 Esbatech Alcon Biomed Res Unit Humanizacion de anticuerpos de conejos usando una estructura de anticuerpos universal.
KR101737466B1 (ko) * 2008-06-25 2017-05-18 에스바테크 - 어 노바티스 컴파니 엘엘씨 Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
WO2009155723A2 (en) 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
US8637022B2 (en) 2008-06-30 2014-01-28 Esbatech, An Alcon Biomedical Research Unit Llc Functionalized polypeptides
CN102770158B (zh) 2009-12-21 2016-10-19 霍夫曼-拉罗奇有限公司 抗体配制剂
WO2012076670A2 (en) 2010-12-10 2012-06-14 Novartis Ag Antibody formulation
CA2824422A1 (en) * 2011-01-13 2012-07-19 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
RU2013155695A (ru) * 2011-06-30 2015-08-10 Дженентек, Инк. Препараты антител против с-мет
AU2012325232B2 (en) * 2011-10-20 2017-08-31 Esbatech - A Novartis Company Llc Stable multiple antigen-binding antibody
KR102373259B1 (ko) 2012-05-03 2022-03-17 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
JOP20200175A1 (ar) 2012-07-03 2017-06-16 Novartis Ag حقنة
UA117466C2 (uk) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
MX365567B (es) 2013-03-13 2019-06-07 Genentech Inc Formulaciones de anticuerpo.
WO2015086830A1 (en) * 2013-12-13 2015-06-18 Delenex Therapeutics Ag Skin penetrating polypeptides
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
CA2952822A1 (en) * 2014-06-17 2015-12-23 Clearside Biomedical, Inc. Methods and devices for treating posterior ocular disorders
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
CN111867631A (zh) 2018-03-16 2020-10-30 诺华股份有限公司 治疗眼部疾病的方法
KR20210106476A (ko) 2018-12-18 2021-08-30 노파르티스 아게 고농도의 항-vegf 항체를 함유하는 단백질 용액 제형

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Jeffrey S Heier;Intravitreal Aflibrcept for AMD:2-year Results;Retina Today,2012-03-01,pages 49-51.
Mantel et al.;Reducing the clinical burden of ranibizumab treatment for neovascular age-relaaaaated macular degeneration using an individually planned regimen;British Journal of Ophthalmology,vol.98,no.9,2014-04-10,pages 1192-1196.
Mantel et al.;Reducing the clinical burden of ranibizumab treatment for neovascular age-relaaaaated macular degeneration using an individually planned regimen;British Journal of Ophthalmology,vol.98,no.9,2014-04-10,pages 1192-1196. Pravin Dugel;Results of ESBA 1008,a Single-Chain Antibody Fragment,for the Treatment of Neovascular AMD;2014-08-08,page 5 pp.http://eyetube.net/series/daily-coverage-san-diego-august-2014/asile Jeffrey S Heier;Intravitreal Aflibrcept for AMD:2-year Results;Retina Today,2012-03-01,pages 49-51. *
Pravin Dugel;Results of ESBA 1008,a Single-Chain Antibody Fragment,for the Treatment of Neovascular AMD;2014-08-08,page 5 pp.http://eyetube.net/series/daily-coverage-san-diego-august-2014/asile

Also Published As

Publication number Publication date
IL265497B (en) 2021-06-30
US11098110B2 (en) 2021-08-24
CA2966646A1 (en) 2016-05-12
KR102588846B1 (ko) 2023-10-16
BR112017008660A2 (pt) 2017-12-26
IL251642A0 (en) 2017-06-29
TWI806150B (zh) 2023-06-21
AU2020220210A1 (en) 2020-10-01
EA201790989A1 (ru) 2017-09-29
US20160130337A1 (en) 2016-05-12
TW201625221A (zh) 2016-07-16
IL283561A (en) 2021-07-29
AU2018278870A1 (en) 2019-01-03
RU2722643C2 (ru) 2020-06-02
EP3215122C0 (en) 2025-08-13
IL280087A (en) 2021-03-01
MX2017005874A (es) 2017-06-26
JP2025004075A (ja) 2025-01-14
BR112017008093A2 (pt) 2018-03-13
AU2020220210B2 (en) 2022-01-20
MX2021006768A (es) 2021-07-15
WO2016073915A1 (en) 2016-05-12
AU2018278870B2 (en) 2020-05-28
AU2018274882B2 (en) 2020-07-09
PH12021550147A1 (en) 2023-01-23
EP3215122A1 (en) 2017-09-13
CL2017001117A1 (es) 2018-01-26
RU2020114917A3 (OSRAM) 2022-01-17
US12371481B2 (en) 2025-07-29
IL265497A (en) 2019-05-30
PH12017500843A1 (en) 2017-10-30
KR20170082526A (ko) 2017-07-14
JP2022141923A (ja) 2022-09-29
AU2020244614A1 (en) 2020-11-05
TW202146049A (zh) 2021-12-16
KR20170076781A (ko) 2017-07-04
CN120938921A (zh) 2025-11-14
WO2016073918A1 (en) 2016-05-12
AU2018274882A1 (en) 2018-12-20
AU2020244614B2 (en) 2023-06-01
GT201700096A (es) 2019-10-10
SG10201913565RA (en) 2020-02-27
MY193913A (en) 2022-11-01
US10035850B2 (en) 2018-07-31
MY183807A (en) 2021-03-16
JP2017534638A (ja) 2017-11-24
AU2015342815B2 (en) 2018-12-13
AU2015342818A1 (en) 2017-05-11
JP6667519B2 (ja) 2020-03-18
MX383808B (es) 2025-03-14
ECSP17034829A (es) 2019-02-28
JP2017538674A (ja) 2017-12-28
MX383399B (es) 2025-03-13
KR20230066649A (ko) 2023-05-16
US20180298092A1 (en) 2018-10-18
TN2017000128A1 (en) 2018-10-19
JP2020193212A (ja) 2020-12-03
RU2017119647A (ru) 2018-12-07
JP6753848B2 (ja) 2020-09-09
CN114081951A (zh) 2022-02-25
TWI738632B (zh) 2021-09-11
AU2015342815A1 (en) 2017-05-11
PH12017500844A1 (en) 2017-10-30
SG11201702954XA (en) 2017-05-30
KR102724014B1 (ko) 2024-10-31
RU2020114917A (ru) 2020-05-22
TWI761959B (zh) 2022-04-21
AU2015342818B2 (en) 2019-01-03
US20160340420A1 (en) 2016-11-24
IL251696A0 (en) 2017-06-29
CA2966758A1 (en) 2016-05-12
MX2017005875A (es) 2017-06-26
IL251642B (en) 2021-02-28
NZ730821A (en) 2019-11-29
CN106999581A (zh) 2017-08-01
TW201625306A (zh) 2016-07-16
EP3215122B1 (en) 2025-08-13
CO2017004596A2 (es) 2017-08-31
IL280087B (en) 2022-02-01
PE20170780A1 (es) 2017-07-04
US20200270336A1 (en) 2020-08-27
TW202103735A (zh) 2021-02-01
EP3215123A1 (en) 2017-09-13
KR20240161204A (ko) 2024-11-12
US12049495B2 (en) 2024-07-30
JP7080263B2 (ja) 2022-06-03
PH12017500844B1 (en) 2021-05-05
SG11201702909QA (en) 2017-05-30
US10689438B2 (en) 2020-06-23
CL2017001115A1 (es) 2018-01-26
JP2020079242A (ja) 2020-05-28
US20210340242A1 (en) 2021-11-04
RU2017119647A3 (OSRAM) 2019-05-29
IL283561B (en) 2022-01-01
CN107635580A (zh) 2018-01-26

Similar Documents

Publication Publication Date Title
TWI705827B (zh) 治療眼部疾病之方法
AU2021286278C1 (en) Methods for treating ocular diseases
CA3149706A1 (en) Methods for treating ocular diseases
RU2771900C2 (ru) Способ лечения болезней глаз
US20230416351A1 (en) Vegf antagonist for use in methods for treating ocular diseases